Kevin Bitterman

Follica, Inc. develops therapies for hair follicle disorders. The firm provides an out-patient therapy coupled with an at-home system for the treatment of androgenetic alopecia (hair loss) and medical device development fields to develop and commercialize its product platform. The company was founded by Rox R. Anderson, George Cotsarelis, Vera Price, Daphne Zohar, David Steinberg, and Bernat Olle in 2006 and is headquartered in Boston, MA.

Solace Pharmaceuticals, Inc. develops therapies for the treatment of neuropathic pain. It offers therapies for neuropathic and inflammatory pain. It offers discovery and development of innovative therapies for pain through in-house drug discovery and development programs as well as through selected partnerships. The company was founded in March 2006 by Allan Basbaum, Bruce Bean, Joyce Deleo and Tony Yaksh and is headquartered in Boston, MA.

TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA.

Biolex Therapeutics, Inc. developed and produced drugs. The company was founded in 1997 and was headquartered in Pittsboro, NC.

Visterra, Inc. Is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antibody-based therapies for kidney diseases, and other chronic diseases. It focuses on its research technology platform, HIEROTOPE technology. The company was founded by Alan L. Crane, Kevin J. Bitterman and Ram Sasisekharan on December 20, 2007 and is headquartered in Waltham, MA.

InSeal Medical Ltd. engages in developing and manufacturing of percutaneous vascular closure devices. The company was founded by Avi Penner and is headquartered in Caesarea, Israel.

Direct Vet Marketing, Inc. provides cloud-based prescription management, pharmacy services, marketing solutions and practice analytics for equine and companion animal veterinary practitioners. It offers online ordering and home delivery of prescription drugs, compounded medications, and therapeutic diets. The company was founded by David Evans Shaw and Benjamin J. Shaw in 2010 and is headquartered in Portland, Maine.

Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA.

Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA.

Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA.

Kinaset Therapeutics, Inc. engages in the provision of pharmaceutical services. It develops therapeutics for intractable diseases including severe asthma. The company was founded by Robert Clarke, Roger Heerman, and Frazer Morgan and is headquartered in Medfield, MA.

Vedere Bio, Inc. develops cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss. The company was founded in June 2019 and is headquartered in Cambridge, MA.

Remix Therapeutics, Inc. operates as a biotechnology company. It involves in developing small molecule therapies which are designed to reprogram RNA processing to address the underlying drivers of disease. The company was founded by Pete Smith and is headquartered in Cambridge, MA.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

New England Venture Capital Association, Inc. is a non-profit organization which operates as a catalyst, and advocate, and a resource for the innovation economy. The company is headquartered in Cambridge, MA.

Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets.

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA.

Judo Bio, Inc. operates as a biotechnology company. The company is based in Cambridge, MA. The company was founded in 2021 by Chelsea Place Johnson.

Atlas Venture Life Science Advisors LLC (Atlas Venture) is a venture capital firm founded in 2014. The firm is headquartered in Cambridge, Massachusetts.